Functional polymorphisms of the cytochrome P450 1A2 (CYP1A2) gene and prolonged QTc interval in schizophrenia

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 31, Issue 6, 2007, Pages 1297-1302

  Tay, Joshua K X ^a   Tan, Chay Hoon ^a   Chong, Siow Ann ^b   Tan, Ene Choo ^a,c  

^a NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^b INSTITUTE OF MENTAL HEALTH   (Singapore)

^c KK WOMEN'S AND CHILDREN'S HOSPITAL   (Singapore)

Author keywords

Antipsychotics; CYP1A2 gene; Genetic polymorphisms; Haplotype analysis; QTc interval

Indexed keywords

CARBAMAZEPINE; CHLORPROMAZINE; CYTOCHROME P450 1A2; DIAZEPAM; FLUPENTIXOL; FLUPHENAZINE; FLUVOXAMINE; HALOPERIDOL; LITHIUM; NEUROLEPTIC AGENT; PHENYTOIN; PIPOTIAZINE; RISPERIDONE; SULPIRIDE; THIORIDAZINE; TRIFLUOPERAZINE; VALPROIC ACID; ZUCLOPENTHIXOL;

ADULT; ALLELE; ARTICLE; DISEASE MARKER; DNA POLYMORPHISM; ELECTROENCEPHALOGRAPHY; FEMALE; GENOTYPE; HAPLOTYPE; HUMAN; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; QT INTERVAL; QT PROLONGATION; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; RISK; SCHIZOPHRENIA; STATISTICAL SIGNIFICANCE; VENOUS BLOOD;

ADULT; AGED; ANTIPSYCHOTIC AGENTS; CYTOCHROME P-450 CYP1A2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; LONG QT SYNDROME; MALE; MIDDLE AGED; POLYMORPHISM, GENETIC; SCHIZOPHRENIA;

EID: 34447556691     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.pnpbp.2007.05.013     Document Type: Article

References (34)

1. American Psychiatric Association. Practice guidelines for the treatment of patients with schizophrenia (1997), American Psychiatric Press, Washington
2. Basile V.S., Ozdemir V., Masellis M., Walker M.L., Meltzer H.Y., Lieberman J.A., et al. A functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene: association with tardive dyskinesia in schizophrenia. Mol Psychiatry 5 (2000) 410-417
3. Bazett H.C. An analysis of the time relations of electrocardiograms. Heart 7 (1920) 353-367
4. Bertilsson L., Carrillo J.A., Dahl M.L., Llerena A., Alm C., Bondesson U., et al. Clozapine disposition covaries with CYP1A2 activity determined by a caffeine test. Br J Clin Pharmacol 38 (1994) 471-473
5. Brosen K., and Gram L.F. Clinical significance of the sparteine/debrisoquine oxidation polymorphism. Eur J Clin Pharmacol 36 (1989) 537-547
6. Carrillo J.A., Ramos S.I., Herraiz A.G., Llerena A., Agundez J.A., Berecz R., et al. Pharmacokinetic interaction of fluvoxamine and thioridazine in schizophrenic patients. J Clin Psychopharmacol 19 (1999) 494-499
7. Chong S.A., Tan E.C., and Tan C.H. Mythily. Smoking and tardive dyskinesia: lack of involvement of the CYP1A2 gene. J Psychiatry Neurosci 28 (2003) 185-189
8. K1, and hERG: QT prolongation, structure activity relationship, and network analysis. Pharm Res 23 (2006) 1133-1143
9. Dahl M.L. Cytochrome P450 phenotyping/genotyping in patients receiving antipsychotics: useful aid to prescribing?. Clin Pharmacokinet 41 (2002) 453-470
10. Glassman A.H., and Bigger J.T. Antipsychotic drugs: prolonged QTc interval, torsades de pointes, and sudden death. Am J Psychiatry 158 (2001) 1774-1782
11. Hamdy S.I., Hiratsuka M., Narahara K., Endo N., El-Enany M., Moursi N., et al. Genotyping of four genetic polymorphisms in the CYP1A2 gene in the Egyptian population. Br J Clin Pharmacol 55 (2003) 321-324
12. Heinrich T.W., Biblo L.A., and Schneider J. Torsades de pointes associated with ziprasidone. Psychosomatics 47 (2006) 264-268
13. Jibson M.D., and Tandon R. An overview of antischizophrenic medications. CNS News (2004) 109-115 December
14. Kalow W., and Tang B.K. Caffeine as a metabolic probe: exploration of the enzyme-inducing effect of cigarette smoking. Clin Pharmacol Ther 49 (1991) 44-48
15. Kane J.M., Aguglia E., Altamura C., Ayuso Gutierrez J.L., and Brunello N. Guidelines for depot antipsychotic treatment in schizophrenia. Eur Neuropsychopharmacol 8 (1998) 55-66
16. Kelly H.G., Fay J.E., and Laverty S.G. Thioridazine hydrochloride (Mellaril): its effect on the electrocardiogram and a report of two fatalities with electrocardiographic abnormalities. Can Med Assoc J 89 (1963) 546-554
17. Matsumoto C., Ohmori O., Shinkai T., Hori H., and Nakamura J. Genetic association analysis of functional polymorphisms in the cytochrome P450 1A2 (CYP1A2) gene with tardive dyskinesia in Japanese patients with schizophrenia. Psychiatr Genet 14 (2004) 209-213
18. Nakajima M., Yokoi T., Mizutani M., Kinoshita M., Funayama M., and Kamataki T. Genetic polymorphism in the 5′-flanking region of human CYP1A2 gene: effect on the CYP1A2 inducibility in humans. J Biochem (Tokyo) 25 (1999) 803-808
19. Okey A.B. Enzyme induction in the cytochrome P-450 system. Pharmacol Ther 45 (1990) 241-498
20. Otani K., and Aoshima T. Pharmacogenetics of classical and new antipsychotic drugs. Ther Drug Monit 22 (2000) 118-121
21. Ozdemir V., Kalow W., Posner P., Collins E.J., Kennedy J.L., Tang B.K., et al. CYP1A2 activity as measured by a caffeine test predicts clozapine and active metabolite steady-state concentration in patients with schizophrenia. J Clin Psychopharmacol 21 (2001) 398-407
22. Ozdemir V., Aklillu E., Mee S., Bertilsson L., Albers L.J., Graham J.E., et al. Pharmacogenetics for off-patent antipsychotics: reframing the risk for tardive dyskinesia and access to essential medicines. Expert Opin Pharmacother 7 (2006) 119-133
23. Pavanello S., Pulliero A., Lupi S., Gregorio P., and Clonfero E. Influence of the genetic polymorphism in the 5′-noncoding region of the CYP1A2 gene on CYP1A2 phenotype and urinary mutagenicity in smokers. Mutat Res 587 (2005) 59-66
24. Ray W.A., Meredith S., Thapa P.B., Meador K.G., Hall K., and Murray KT. Antipsychotics and the risk of sudden cardiac death. Arch Gen Psychiatry 58 (2001) 1161-1167
25. Ring B.J., Catlow J., Lindsay T.J., Gillespie T., Roskos L.K., Cerimele B.J., et al. Identification of the human cytochromes P450 responsible for the in vitro formation of the major oxidative metabolites of the antipsychotic agent olanzapine. J Pharmacol Exp Ther 276 (1996) 658-666
26. Sachse C., Brockmoller J., Bauer S., and Roots I. Functional significance of a C → A polymorphism in intron 1 of the cytochrome P450 CYP1A2 gene tested with caffeine. Br J Clin Pharmacol 47 (1999) 445-449
27. Schulze T.G., Schumacher J., Muller D.J., Krauss H., Alfter D., Maroldt A., et al. Lack of association between a functional polymorphism of the cytochrome P450 1A2 (CYP1A2) gene and tardive dyskinesia in schizophrenia. Am J Med Genet 105 (2001) 498-501
28. Shimoda K., Someya T., Morita S., Hirokane G., Yokono A., Takahashi S., et al. Lack of impact of CYP1A2 genetic polymorphism (C/A polymorphism at position 734 in intron 1 and G/A polymorphism at position -2964 in the 5′-flanking region of CYP1A2) on the plasma concentration of haloperidol in smoking male Japanese with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 26 (2002) 261-265
29. Shin J.G., Soukhova N., and Flockhart D.A. Effect of antipsychotic drugs on human liver cytochrome P-450 (CYP) isoforms in vitro: preferential inhibition of CYP2D6. Drug Metab Dispos 27 (1999) 1078-1084
30. Stöllberger D., Huber J.O., and Finster J. Antipsochotic drugs and QT prolongation. Int Clin Psychopharmacol 20 (2005) 243-251
31. Tiwari A.K., Deshpande S.N., Rao A.R., Bhatia T., Mukit S.R., Shriharsh V., et al. Genetic susceptibility to tardive dyskinesia in chronic schizophrenia subjects: I. Association of CYP1A2 gene polymorphism. Pharmacogenomics J 5 (2005) 60-69
32. Yap Y.C., and Camm J. Risk of torsades de pointes with non-cardiac drugs. Bmj 320 (2000) 1158-1159
33. Yoshii K., Kobayashi K., Tsumuji M., Tani M., Shimada N., and Chiba K. Identification of human cytochrome P450 isoforms involved in the 7-hydroxylation of chlorpromazine by human liver microsomes. Life Sci 67 (2000) 175-184
34. Zareba W., and Lin D.A. Antipsychotic drugs and QT interval prolongation. Psychiatr Q 74 (2003) 291-306